University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.
Deep Genomics, a Canada-based RNA therapy developer based on research at University of Toronto, has raised $180m in a series C round led by telecoms firm SoftBank’s Vision Fund 2.
The round also featured Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as investment and financial services group Fidelity, Canadian Pension Plan Investment Board, Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures.
Founded in 2015,…
